Research Article
Clinical Application Value of High-Frequency Ultrasound Combined with Detection of Serum High Mobility Group Box 1, Soluble IL-2 Receptor, and Thyroglobulin Antibody in Diagnosing Thyroid Cancer

Ning Li,1 Jiahui Zhang,2 Xiaojiao Meng,1 and Wenliang Yao3

1Department of Ultrasound Medicine, Zibo Central Hospital, 255022 Zibo, Shandong Province, China
2Department of Public Health, Zibo Central Hospital, 255022 Zibo, Shandong Province, China
3Department of Nuclear Medicine, Zibo Central Hospital, 255022 Zibo, Shandong Province, China

Correspondence should be addressed to Wenliang Yao; yaowenliang@zbzxyy.com.cn

Received 28 December 2021; Revised 9 February 2022; Accepted 10 February 2022; Published 29 March 2022

Academic Editor: M. A. Bhagyaveni

Copyright © 2022 Ning Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The aim of this study is to explore the clinical application value of high-frequency ultrasound combined with detection of serum high mobility group box (HMGB-1), soluble IL-2 receptor (SIL-2R), and thyroglobulin antibody (TgAb) in diagnosing thyroid cancer. Methods. By means of retrospective study, 50 thyroid cancer patients treated in our hospital from January 2019 to January 2021 were selected as the thyroid cancer group, 50 patients with benign thyroid lesions were included in the benign lesion group, and 50 healthy individuals examined in our hospital in the same period were included in the control group. All study objects received high-frequency ultrasound examination, and at the same time, their serum HMGB-1, SIL-2R, and TgAb levels were measured. After that, the results of high-frequency ultrasound examination were analyzed, the diagnostic efficacy of different diagnosis methods was explored, and receiver operating characteristic (ROC) curves were plotted. Results. According to the results of high-frequency ultrasound examination, there were significant differences in echogenicity surrounding and inside the lesion, calcification, blood flow distribution, and blood flow parameters between the thyroid cancer group and the benign lesion group ($P < 0.001$); the HMGB-1, SIL-2R, and TgAb levels were statistically different among the three groups ($P < 0.001$), and the level values of HMGB-1, SIL-2R, and TgAb of the thyroid cancer group were, respectively, (12.26 ± 1.32) ng/mL, (108.65 ± 9.75) pmol/L, and (690.65 ± 34.47) IU/mL; the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of high-frequency ultrasound combined with detection of serum HMGB-1, SIL-2R, and TgAb were, respectively, 98.0%, 95.0%, 90.7%, and 99.0%, and AUC (95%CI) = 0.965 (0.931–0.999). Conclusion. High-frequency ultrasound combined with detection of serum HMGB-1, SIL-2R, and TgAb has a good value in diagnosing thyroid cancer, which should be promoted in practice.

1. Introduction

Thyroid cancer is a malignant tumor originating from thyroid follicular epithelium or parafollicular epithelial cells, and at the early stage, patients do not present specific clinical symptoms and often visit the hospital for painless neck mass or nodule [1, 2]. As the disease progresses, the enlarged lesion tissue can further compress and invade surrounding organs, which makes the patients present dyspnea, dysphagia, jugular varicosity, etc., and some patients also have lung, liver, and bone metastasis, triggering more severe symptoms such as hemoptysis and bone pain [3, 4]. The globally age-standardized incidence of thyroid cancer increased by 20.0% between 1990 and 2013, while in China, it was increased by more than 33.3%, and 143,900 cases of thyroid cancer have been reported in China until 2013 [5, 6]. Some scholars believe that the increasing incidence of thyroid cancer is related to the upgrading of diagnostic techniques in addition to oncogenes, ionizing radiation, iodine intake, and other factors [7]. There is general
agreement among academia that the widespread use of ultrasound and fine-needle aspiration biopsy is an important contributor to the increasing detection rate of thyroid cancer, which has been proven by the fact that the detection rate of thyroid cancer is higher in high-income regions than in middle- and low-income countries [8]. From the practical situation in China, a deeper exploration of diagnostic techniques is beneficial for reducing the medical burden of thyroid cancer and eliminating the impact of diagnostic level on incidence of thyroid cancer, so as to more deeply analyze the real contributing factors to the changing trends in the incidence and mortality of thyroid cancer in China and to adopt active and effective response measures.

At this stage, ultrasonic inspection, biopsy needle aspiration, and serologic testing are the most common diagnostic modalities for thyroid cancer in clinic. Compared with biopsy, ultrasonic and serologic testing are safer, more convenient to operate, and more acceptable to patients, and patients are less prone to adverse effects such as nausea and vomiting. Recently, serum HMGB-1, SIL-2R, TgAb and other markers have been gradually applied in diagnosing thyroid cancer, of which HMGB-1 is a highly conserved DNA marker capable of mediating tumor initiation and progression, which is highly expressed in malignant tumors but has a certain false negative rate, so it is often used as a secondary indicator in combination with SIL-2R, one of the immunosuppressive agents that can attenuate the endocrine effects in body, reduce the immune system capacity, thus promoting tumor cell differentiation and proliferation. TgAb is a specific thyroid autoantibody able to reduce the secretion of thyroid hormones and eventually impair thyroid function, thus showing higher expression in patients with thyroid lesions than in the normal individual. Some scholars have found that the Kappa of the combination of TgAb and contrast-enhanced ultrasound for the diagnosis of thyroid cancer is 0.864, indicating that TgAb can effectively assist ultrasonic inspection [9]. As one type of the ultrasonic inspection, high-frequency ultrasound can clearly demonstrate the inner thyroid mass, so that physicians can visually observe the internal and peripheral blood flow distribution of the tumor, and then judge the parenchyma of thyroid masses. Currently, there are no studies combining high-frequency ultrasound with HMGB-1, SIL-2R, and TgAb, and based on this, this article will explore the diagnostic efficacy of combining the four to provide a new way for diagnosing thyroid cancer in China.

2. Materials and Methods

2.1. Enrollment of Study Objects. Inclusion criteria were patients (1) being diagnosed with thyroid nodule after postoperative pathological diagnosis, including benign thyroid nodule or thyroid cancer [10]; (2) having surgical indicators and accepting the surgical treatment; (3) treated in our hospital in the whole course and had complete clinical data; (4) being diagnosed for the first time; and (5) being at least 18 years old.

Exclusion criteria were patients (1) being not able to communicate with others due to factors such as hearing disorder, language disorder, unconsciousness, or mental diseases; (2) quitting the treatment before completion; (3) having other severe organic diseases; (4) having received treatment before, including thyroid surgery, iodine therapy, and antithyroid drug therapy; and (5) having immune dysfunction and coagulation disorders.

2.2. General Data of Study Objects. A total of 50 thyroid cancer patients treated in our hospital from January 2019 to January 2021 were selected as the thyroid cancer group, 50 patients with benign thyroid lesions were included in the benign lesion group, and 50 healthy individuals examined in our hospital in the same period were included in the control group. In the thyroid cancer group, the mean diameter of patients’ nodules was (3.01 ± 0.32) cm, and among these patients, there were 20 cases with pathological follicular carcinoma, 24 cases with papillary carcinoma, 5 cases with undifferentiated carcinoma, and 1 case with medullary carcinoma; 32 cases in stage II, and 18 cases in stage III; 21 cases had metastasis, and 29 cases had no metastasis; 30 cases with well differentiation, 8 cases with moderate differentiation, and 12 cases with poor differentiation. In the benign lesion group, there were 32 cases with thyroid nodular goiter and 18 cases with thyroid adenoma.

Among the thyroid cancer group, benign lesion group, and control group, no statistical differences in gender ratio (18 males and 32 females vs 20 males and 30 females vs 18 males and 32 females) and mean age (48.62 ± 15.49 vs 48.48 ± 18.45 vs 48.50 ± 16.82 years) were found (P > 0.05), presenting the sense of study.

2.3. Moral Consideration. The study met the principles in World Medical Association Declaration of Helsinki (2013) [11], and after enrollment, the study team explained the study purpose, meaning, contents, and confidentiality to the patients and asked the patients to sign the informed consent.

2.4. Methods. All study objects received high-frequency ultrasound examination, and at the same time, their serum HMGB-1, SIL-2R, and TgAb levels were measured. In the combined detection of high-frequency ultrasound and serological indicators, if one of the results was positive, it was determined as positive; if both results were negative, it was determined as negative.

2.4.1. High-Frequency Ultrasound Examination. The instrument used was high-frequency color Doppler ultrasonic diagnostic apparatus (GE Healthcare Voluson P6; NMPA Registration (I) no. 20152062178) with a 10 MHz linear array probe. The patients were in the spine position to fully expose their neck, and the 2D ultrasound was applied to perform continuous longitudinal and transverse scanning to their thyroid, so as to measure the size, morphology, internal echo, and other data of thyroid; record the information including size, amount, and boundary of intraglandular mass; and observe for envelope, rear attenuation, and cervical lymph nodes, especially the
2.4.2. Serological Examination. Five mL of fasting venous blood was drawn from the patients in the morning to separate serum after centrifuging at 2,000 r/min and then to measure the HMGB-1, SIL-2R, and TgAb levels by the ELASA method (Beijing Kewei Clinical Diagnostic Reagent Inc.; NMPA approval no. S20060028). The operation was in strict accordance with the specifications, and the positive range was subject to that on the kit.

2.5. Observation Criteria

(1) Results of high-frequency ultrasound examination. Two dimensional ultrasound findings, blood flow distribution, and blood flow parameters of the thyroid cancer group and the benign lesion group were analyzed. Rating standard for blood flow distribution: level 0 referring to no blood signal inside or surrounding the lesion; level I referring to blood signal distribution range inside the lesion was less than 1/3 of the lesion area or that surrounding the lesion was less than 1/3 of the lesion perimeter; level II referring to blood signal distribution range inside the lesion was over 1/3 of the lesion area or that surrounding the lesion was over 1/3 of the lesion perimeter; and level III referring to full blood flow signal inside the lesion or the blood flow signal surrounding the lesion almost took up the entire perimeter.

(2) Serological marker level. The serum HMGB-1, SIL-2R, and TgAb levels were compared among study objects in the three groups.

(3) Diagnostic efficacy of different diagnosis methods. The diagnosis results from high-frequency ultrasound, HMGB-1, SIL-2R, and TgAb and the combination of the four were recorded, and the diagnostic efficacy was calculated. ① Sensitivity: number of true positive cases/(number of true positive cases + number of false negative cases) * 100%; ② specificity: number of true negative cases/(number of true negative cases + number of false positive cases) * 100%; ③ positive predictive value (PPV): number of true positive cases/(number of true positive cases + number of false positive cases); and ④ negative predictive value (NPV): number of true negative cases/(number of false negative cases + number of true negative cases).

(4) ROC curve. According to the diagnosis results, the ROC curves of high-frequency ultrasound, HMGB-1, SIL-2R, and TgAb, and the combination of the four were plotted.

2.6. Statistical Processing. In this study, the data processing software was SPSS20.0, the picture drawing software was GraphPad Prism 7 (GraphPad Software, San Diego, USA), the items included were enumeration data and measurement data, the methods used were X² test and t-test, and differences were considered statistically significant at P < 0.05.

3. Results

3.1. Results of High-Frequency Ultrasound Examination. In the thyroid cancer group, 38 cases showed no echogenicity surrounding the lesion, 35 cases showed low echogenicity inside the lesion, and there were 32 microcalcifications; and in the benign lesion group, 10 cases showed no echogenicity surrounding the lesion, 5 cases showed low echogenicity inside the lesion, and there were 4 microcalcifications (X² = 31.410, X² = 37.500, X² = 34.028, P < 0.001). In the thyroid cancer group, there were 10 cases with level 0-I blood flow distribution, and 40 cases with levels II-III; and in the benign lesion group, there were 42 cases with level 0-I blood flow distribution, and 8 cases with levels II-III (X² = 41.026, P < 0.001). In the thyroid cancer group, the RSV was (44.65 ± 5.37) cm/s, and RI was (0.71 ± 0.09); while in the benign lesion group, the RSV was (31.22 ± 4.70) cm/s, and RI was (0.51 ± 0.08) (t = 13.307, t = 11.744, P < 0.001). See Figure 1.

3.2. Levels of Serum Markers. Among the thyroid cancer group, benign lesion group, and control group, the HMGB-1, SIL-2R, and TgAb levels were statistically different (P < 0.001). See Table 1.

3.3. Diagnostic Efficacy of Different Diagnosis Methods. The sensitivity, specificity, PPV, and NPV of jointly applying high-frequency ultrasound and detection of serum HMGB-1, SIL-2R, and TgAb were, respectively, 98.0%, 95.0%, 90.7%, and 99.0%. See Tables 2 and 3.

3.4. ROC Curve. For combined detection, AUC (95%CI) = 0.965 (0.931–0.999). See Figure 2.

4. Discussion

Ultrasonic inspection has significant advantages such as easy operation, low cost, and high safety, which can intuitively demonstrate the characteristic thyroid gland with a relatively shallow location and few vessel route variations, thus it is regarded as the preferred diagnostic modality for thyroid cancer. There is a relationship between the elevated detection rate of thyroid cancer and the optimization of ultrasound technology worldwide in recent years, and the improved resolution of the high-frequency probe can show the internal fine structure of the mass more clear, which is beneficial for physicians to observe the lesions of the gland and judge the mass parenchyma [6, 12–14]. The results of the high-frequency ultrasound examination showed that patients with thyroid cancer presented obvious ultrasonographic features [15, 16], and between the thyroid cancer group and the
benign lesion group, the echogenicity inside and surrounding the lesion, calcification, blood flow distribution, and blood flow parameters were significantly different \( (P<0.001) \). In the thyroid cancer group, 38 cases showed no echogenicity surrounding the lesion and 35 cases showed low echogenicity inside the lesion; while in the benign group, respectively, 10 cases and 5 cases, demonstrating that thyroid sonograms mostly showed an irregular morphology and indistinct borders, which was because infiltrative growth of thyroid tumors into the periphery, large and overlapping cancer cells, and few stromal components, so that intensely reflective interface could not be formed and hypo-echogenicity was presented in ultrasound images. Meanwhile, 32 microcalcifications were detected in the thyroid cancer group, while there were only 4 in the benign lesion group, confirming that microcalcifications were the most specific indicator in terms of thyroid cancer diagnosis. Thyrocytes grow more rapidly, and hyperproliferation of tissues leads to deposition of calcium salts to the point of calcification [17], so calcification is a key element in distinguishing benign from malignant tumors. The differences in blood flow parameters between the thyroid cancer group and the benign lesion group may lie in the abundant blood vessels and faster blood flow rate in the thyroid cancer lesions, while the blood supply of benign lesions is derived from preexisting vessels [18], so the PSV and PI were significantly higher in the thyroid cancer group.

Angell et al. reported that combining ultrasound with serological indicators can improve the diagnostic efficacy, which is superior to that of single ultrasound examination [19]. The study found that the sensitivity and specificity of high-frequency ultrasound alone were, respectively, 90.0%
and 90.0%, and when jointly applying HMGB-1, SIL-2R, and TgAb, the sensitivity, specificity, PPV, and NPV were, respectively, 98.0%, 95.0%, 90.7%, and 99.0%, and AUC (95% CI) = 0.965 (0.931–0.999). HMGB-1 is widespread in mammalian DNA and is able to regulate gene transcription, recombination and differentiation, thereby affecting tumor initiation and progression [20]. Also, it was found to be highly expressed in some malignancies, such as lung and liver cancer, indicating that this substance acts as a cancer promoting factor. SIL-2R is able to neutralize interleukin-2 surrounding activated T cells, inhibit the cloning of activated T cells, and thus affect the body’s immunity [21, 22]. Moreover, most malignant tumors will lead to abnormal immune function in the body and an increase of SIL-2R level, so there is a relationship between SIL-2R and malignant tumors. The study results showed that the HMGB-1 and SIL-2R levels among the thyroid cancer group, benign lesion group and control group were significantly different (P < 0.001). TgAb is a soluble iodinated glycoprotein synthesized and secreted by thyroid epithelial cells that is able to exert mutual effect with binding antibodies via Fc receptors to activate NK cells and then attack target cells, causing destruction of thyroid cells [23]. Scholars Kang et al. stated that TgAb can serve as an important factor in predicting thyroid cancer, and its diagnostic efficacy in combination with ultrasound is superior to that of a single test [24]. This study found that the diagnostic sensitivity and specificity of ultrasound combined with three serum markers were significantly superior to a single test, confirming that this assay can sufficiently improve the clinical detection rate and is worthy of social promotion.

In conclusion, high-frequency ultrasound combined with serum HMGB-1, SIL-2R, and TgAb has a good social value in detecting thyroid cancer and is conducive to relieving the medical burden of thyroid cancer treatment in China, which should be generalized in practice.

Data Availability

The data used to support the findings of this study are available on reasonable request from the corresponding author.

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

[1] Y. Guo, J. Xu, X. Li et al., “Classification and diagnosis of residual thyroid tissue in SPECT images based on fine-tuning deep convolutional neural network,” Frontiers in Oncology, vol. 11, p. 762643, 2021.
[2] A. W. Lee, R. A. Mendoza, S. Aman, R. Hsu, and L. Liu, “Thyroid cancer incidence disparities among ethnic Asian American populations, 1990-2014.[J],” Annals of Epidemiology, vol. 66, pp. 28–36, 2021, undefined: undefined.
[3] V. A. Paulson, E. R. Rudzinski, and D. S. Hawkins, “Thyroid cancer in the pediatric population,” Genes (Basel), vol. 10, no. 9, p. 723, 2019.
[4] M. Steinschneider, J. Pitaro, S. Koren, Y. Mizrakli, C. Benbassat, and L. M. Kalovitch, “Differentiated thyroid cancer with biochemical incomplete response: clinico-pathological characteristics and long term disease outcomes.[J],” Cancers, vol. 13, p. 5422, 2021 undefined.
[5] M. Radzina, M. Ratniece, D. S. Putrins, L. Saule, and V. Cantisani, “Performance of contrast-enhanced ultrasound in thyroid nodules: review of current state and future perspectives.[J],” Cancers, vol. 13, p. 5469, 2021 undefined.
[6] L. Scappaticcio, M. I. Maiorino, S. Iorio et al., “Exploring the performance of ultrasound risk stratification systems in thyroid nodules of pediatric patients.,” Cancers, vol. 13, p. 5304, 2021 undefined.
[7] K. Gonda, M. Shubata, I. Nakamura et al., “[Myeloid-derived suppressor cells in cancer patients].”[J],” Gai To Kagaku Ryoho, vol. 39, pp. 1797–1799, 2012.
[8] C. D. Seib and J. A. Sosa, “Understanding of the epidemiology of thyroid cancer,” Endocrinology and Metabolism Clinics of North America, vol. 48, no. 1, pp. 23–35, 2019.
[9] J. I. Botella-Carretero, A. Prados, L. Manzano et al., “The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal,” European Journal of Endocrinology, vol. 153, no. 2, pp. 223–230, 2005.
[10] L. K. Seppälä, L.-M. Madanat-Harjuoja, M. K. Leinonen, M. Lääperi, and K. Vettenranta, “Maternal thyroid disease and the risk of childhood cancer in the offspring.[J],” Cancers, vol. 13, p. 5409, 2021 undefined.
[11] World Medical Association, "World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects," JAMA, vol. 310, no. 20, pp. 2191–2194, 2013.

[12] J. Komorowski, J. Jankewicz, and H. Stepień, “Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours.],” Cytobios, vol. 101, pp. 151–159, 2000.

[13] M. Klaín, J. Hadoux, C. Nappi et al., “Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives.[],” Endocrine, vol. 75, no. 2, pp. 330–337, 2021, undefined: undefined.

[14] A. J. Bauer, "Pediatric thyroid cancer: genetics, therapeutics and outcome," Endocrinology and Metabolism Clinics of North America, vol. 49, no. 4, pp. 589–611, 2020.

[15] S. Mariotti, P. Caturegli, G. Barbesino, G. F. Del Prete, L. Chiovato, and A. Pinchera, “Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism,” Journal of Endocrinological Investigation, vol. 14, no. 9, pp. 777–781, 1991.

[16] S. Wirth, M.-E. Syleouni, N. Karavasiloglou et al., “Incidence and mortality trends of thyroid cancer from 1980 to 2016.[],” Swiss Medical Weekly, vol. 151, p. w30029, 2021.

[17] S. Mariotti, G. Barbesino, P. Caturegli et al., “Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma,” Journal of Endocrinological Investigation, vol. 17, no. 11, pp. 861–867, 1994.

[18] M. Fridman, O. Krasko, L. Levin, I. Veyalkin, and A. K.-y. Lam, “Comparative pathological characteristics of papillary thyroid carcinoma with second primary non-thyroid malignancies in the region affected by the Chernobyl accident,” Pathology, Research & Practice, vol. 228, p. 153658, 2021.

[19] T. E. Angell and E. K. Alexander, “Thyroid nodules and thyroid cancer in the pregnant woman,” Endocrinology and Metabolism Clinics of North America, vol. 48, no. 3, pp. 557–567, 2019.

[20] J. Zhao, L. Qian, Y. Liu, and X. Tan, “A long-term retrospective study of ultrasound-guided microwave ablation of thyroid benign solid nodules,” International Journal of Hyperthermia, vol. 38, no. 1, pp. 1566–1570, 2021.

[21] E. J. Ha, S. R. Chung, D. G. Na et al., “2021 Korean thyroid imaging reporting and data system and imaging-based management of thyroid nodules: Korean society of thyroid radiology consensus statement and recommendations.[],” Korean Journal of Radiology, vol. 22, no. 12, p. 2094, 2021 undefined: undefined.

[22] K. Kim, J. S. Bae, and J. S. Kim, “Measurement of thyroglobulin level in lateral neck lymph node fine needle aspiration washout fluid in papillary thyroid cancer,” Gland Surgery, vol. 10, no. 9, pp. 2686–2694, 2021.

[23] L. Knappe and L. Giovanella, “Life after thyroid cancer: the role of thyroglobulin and thyroglobulin antibodies for post-operative follow-up.[],” Expert Review of Endocrinology and Metabolism, vol. 16, no. 6, pp. 273–279, 2021, undefined.

[24] M. Kang, T. S. Wang, T. W. Yen, K. Doffek, D. B. Evans, and S. Dream, “The clinical utility of preoperative thyroglobulin for surgical decision making in thyroid disease.[],” Journal of Surgical Research, vol. 270, pp. 230–235, 2021.